arrow
C

Chang-Ki Min

seoul st mary's hospital
H指数:34
被引数:5,129

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-world effectiveness of bortezomib maintenance following VMP induction in transplant-ineligible multiple myeloma: a target trial emulation study

移植不适格多发性骨髓瘤患者中硼替佐米维持治疗在VMP诱导后的真实世界有效性:一项目标试验模拟研究

2026-03-230
OAAI
A multicentre prospective phase II study of rituximab combined with bortezomib, lenalidomide and dexamethasone, followed by lenalidomide maintenance (R-VRD) in patients with Waldenström's macroglobulinaemia (KMM1803)

一项多中心前瞻性II期研究,评估利妥昔单抗联合硼替佐米、来那度胺和地塞米松,随后给予来那度胺维持治疗(R-VRD)在瓦尔登斯特罗姆巨球蛋白血症患者中的疗效(KMM1803)。

2025-11-010
PRE
Ponatinib Monotherapy in Adult Patients with Relapsed or Refractory Philadelphia-Positive Acute Lymphoblastic Leukemia: A Real-World Retrospective Analysis Including Measurable Residual Disease Relapse

波纳替尼单药治疗成人复发性或难治性费城染色体阳性急性淋巴细胞白血病的真实世界回顾性分析:包括可测量微小残留病复发情况

2025-10-010
OAAI
Feasibility of a Total Body Irradiation-Augmented Reduced-Toxicity Conditioning Regimen with an Antithymocyte Globulin/Post-Transplantation Cyclophosphamide Combination for Haploidentical Donor Transplantation in Adult Acute Lymphoblastic Leukemia

异基因供者移植中成人急性淋巴细胞白血病采用抗胸腺细胞球蛋白/移植后环磷酰胺联合方案增敏的全身体外照射增强减毒预处理方案的安全性评估

2025-05-240
PRE
Efficacy and Safety of Bispecific T-Cell Engagers in Relapsed/ Refractory Multiple Myeloma: A Real-World Data-Based Case-Controlled Study

双特异性T细胞接合器治疗复发/难治性多发性骨髓瘤的疗效和安全性: 一项基于真实世界数据的病例对照研究

2025-02-010
PRE
Real-World Efficacy and Safety of Teclistamab for Patients with Released or Refractory Multiple Myeloma: Korean, Nationwide, Retrospective Analysis of an Named Patient Program

托西卡玛单抗在复发或难治性多发性骨髓瘤患者中的真实世界疗效与安全性:韩国全国性回顾性分析(基于指定患者用药计划)

BLOOD
IF23.1
2024-11-050
PRE
Retrospective Analysis of Treatment Outcome Differences with and without Autologous Stem Cell Transplantation in Patients with Dialysis-Dependent Multiple Myeloma (DDMM): KMM2304 Study

回顾性分析自体干细胞移植与未进行自体干细胞移植的透析依赖性多发性骨髓瘤(DDMM)患者治疗结局差异:KMM2304研究

BLOOD
IF23.1
2024-11-050
PRE
A Phase II Clinical Study for Evaluating the Efficacy and Safety of Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone in Transplantation-Eligible Elderly Patients with Newly Diagnosed Multiple Myeloma (KMM2101)

一项评估达拉木单抗、来那度胺、硼替佐米和地塞米松在移植适用老年新诊断多发性骨髓瘤患者中有效性与安全性的II期临床研究(KMM2101)

BLOOD
IF23.1
2024-11-050
PRE